Crinetics Pharmaceuticals CRNX EBITDA

EBITDA at other companies

Neurocrine BiosciencesNBIX

$200.7M+543%

Corcept TherapeuticsCORT

$42.16M+56.4%

MBX Biosciences, Inc.MBX

-$27.2M-2.8%

XER

Xeris Biopharma Holdings, Inc.XERS

$5.5M+14.3%

Amylyx Pharmaceuticals, Inc.AMLX

-$45.65M-6.9%

BridgeBio PharmaBBIO

——

FAQ

What is Crinetics Pharmaceuticals's EBITDA?

Crinetics Pharmaceuticals (CRNX) reported EBITDA of -$139.22M in Q1 2026.

How has Crinetics Pharmaceuticals's EBITDA changed year-over-year?

Crinetics Pharmaceuticals's EBITDA decreased by 26.0% year-over-year, from -$110.48M to -$139.22M.

What is the long-term trend for Crinetics Pharmaceuticals's EBITDA?

Over 4 years (2021 to 2025), Crinetics Pharmaceuticals's EBITDA has grown at a 48.0% compound annual growth rate (CAGR), from -$106.78M to -$512.88M.

What does EBITDA mean?

Earnings before interest, taxes, depreciation, and amortization — EBIT plus the D&A add-back from the cash-flow statement (EBITDA = EBIT + D&A). A proxy for cash earnings that strips out financing, tax, and non-cash charges.